Halozyme ups revolver to $575M, repays term loan and revolver with convertible note proceeds

HALOZYME THERAPEUTICS, INC.

Revolving credit facility increased by $225M to $575M; all other terms unchanged.
Company repaid entire term loan facility and all outstanding revolver borrowings using proceeds from previously issued convertible notes.
Amendment included 11 increase lenders: Bank of America, Wells Fargo, JPMorgan, Citibank, Goldman Sachs, Mizuho, Silicon Valley Bank, and others.
Conditions included pro forma Consolidated Net Leverage Ratio not exceeding 0.25:1.00 less than the permitted level.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.